Nirmatrelvir/ritonavir as a potential treatment for prolonged SARS-CoV-2 infection in immunocompromised patients
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia - 35(2022), 6 vom: 17. Dez., Seite 589-591 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pérez Catalán, I [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 30.11.2022 Date Revised 29.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.37201/req/078.2022 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347656366 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347656366 | ||
| 003 | DE-627 | ||
| 005 | 20231226034340.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.37201/req/078.2022 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1158.xml |
| 035 | |a (DE-627)NLM347656366 | ||
| 035 | |a (NLM)36250675 | ||
| 035 | |a (PII)roig18oct2022 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pérez Catalán, I |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nirmatrelvir/ritonavir as a potential treatment for prolonged SARS-CoV-2 infection in immunocompromised patients |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.11.2022 | ||
| 500 | |a Date Revised 29.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a combination | |
| 650 | 4 | |a nirmatrelvir | |
| 650 | 4 | |a ritonavir | |
| 650 | 4 | |a rituximab | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a García Muñoz, S |e verfasserin |4 aut | |
| 700 | 1 | |a Roig Martí, C |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez Alfaro, I |e verfasserin |4 aut | |
| 700 | 1 | |a Serrano Picazo, L |e verfasserin |4 aut | |
| 700 | 1 | |a Torres García, M |e verfasserin |4 aut | |
| 700 | 1 | |a Reig Valero, R |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrando Piqueres, R |e verfasserin |4 aut | |
| 700 | 1 | |a Mateu Campos, L |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos Rincón, J M |e verfasserin |4 aut | |
| 700 | 1 | |a Usó Blasco, J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia |d 1997 |g 35(2022), 6 vom: 17. Dez., Seite 589-591 |w (DE-627)NLM090649028 |x 1988-9518 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2022 |g number:6 |g day:17 |g month:12 |g pages:589-591 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.37201/req/078.2022 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2022 |e 6 |b 17 |c 12 |h 589-591 | ||